SCHEMBL12469820

SCHEMBL12469820

COc1ccc2c(c1)C(c1ccccc1OCC(C)C)CC(=O)N2

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.67
TP53 P04637 7/20 0.67
POLB P06746 1/20 0.59
LMNA P02545 7/20 0.54
MAPT P10636 1/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TSHR P16473 8/20 0.51
NPSR1 Q6W5P4 4/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPK1 P28482 5/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50
RECQL P46063 1/20 0.50
ALOX15 P16050 2/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469560 0.88 TSHR (0.65) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12470021 0.86 ALDH1A1 (0.65) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL18648916 0.86 SMN1; SMN2 (0.68) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12470194 0.86 POLB (0.78) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12469924 0.86 POLB (0.72) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12698408 0.83 SMN1; SMN2 (0.72) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12469836 0.80 SMN1; SMN2 (1.00) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL12469760 0.78 SMN1; SMN2 (0.78) SMN1; SMN2TP53POLBLMNAMAPT
SCHEMBL880263 0.77 KMT2A (0.60) SMN1; SMN2TP53MEN1KMT2ATSHR
SCHEMBL30866425 0.77 KMT2A (0.60) SMN1; SMN2TP53MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2019-08-27 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-04-20 US disclosed
US-9597325-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-03-21 US disclosed
US-9597325-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-03-21 US disclosed
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-02-16 US disclosed
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2017-02-16 US disclosed
WO-2012050985-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2012-04-19 WO disclosed
WO-2012050985-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107227-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885POLB 1848/4885
US-20170044175-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885POLB 1848/4885
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885POLB 1848/4885
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics GTF2F1, HDGF, GTF3C5 SMN1; SMN2 4673/4885TP53 33/4885POLB 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.